These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 24100744

  • 1. [Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature].
    Vaisbich MH, Henriques Ldos S, Watanabe A, Pereira LM, Metran CC, Malheiros DA, Modanez F, Silva JD, Vieira S, Macedo AC, Massarope B, Furusawa EA, Schvartsman BG.
    J Bras Nefrol; 2013; 35(3):237-41. PubMed ID: 24100744
    [Abstract] [Full Text] [Related]

  • 2. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.
    Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
    [Abstract] [Full Text] [Related]

  • 3. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F, Frémeaux-Bacchi V, Loirat C.
    Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
    [Abstract] [Full Text] [Related]

  • 4. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B.
    Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
    [Abstract] [Full Text] [Related]

  • 5. [A case of atypical hemolytic uremic syndrome successfully weaned from plasma exchange by treatment with eculizumab].
    Nagata A, Ohara A, Wakasugi D, Natori C, Ito S, Taguchi K, Fukami K, Okuda S.
    Nihon Jinzo Gakkai Shi; 2014 Jun; 56(5):606-11. PubMed ID: 25130033
    [Abstract] [Full Text] [Related]

  • 6. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report.
    Giordano M, Castellano G, Messina G, Divella C, Bellantuono R, Puteo F, Colella V, Depalo T, Gesualdo L.
    Pediatrics; 2012 Nov; 130(5):e1385-8. PubMed ID: 23027168
    [Abstract] [Full Text] [Related]

  • 7. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
    Christmann M, Hansen M, Bergmann C, Schwabe D, Brand J, Schneider W.
    Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059
    [Abstract] [Full Text] [Related]

  • 8. Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment.
    Belingheri M, Possenti I, Tel F, Paglialonga F, Testa S, Salardi S, Ardissino G.
    Pediatrics; 2014 Jun; 133(6):e1769-71. PubMed ID: 24843058
    [Abstract] [Full Text] [Related]

  • 9. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S.
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [Abstract] [Full Text] [Related]

  • 10. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.
    Westra D, Wetzels JF, Volokhina EB, van den Heuvel LP, van de Kar NC.
    Neth J Med; 2012 Apr; 70(3):121-9. PubMed ID: 22516576
    [Abstract] [Full Text] [Related]

  • 11. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
    Köse O, Zimmerhackl LB, Jungraithmayr T, Mache C, Nürnberger J.
    Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
    [Abstract] [Full Text] [Related]

  • 12. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C.
    N Engl J Med; 2013 Jun 06; 368(23):2169-81. PubMed ID: 23738544
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A.
    Transfus Apher Sci; 2016 Dec 06; 55(3):357-362. PubMed ID: 27742267
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.
    Am J Kidney Dis; 2016 Jul 06; 68(1):84-93. PubMed ID: 27012908
    [Abstract] [Full Text] [Related]

  • 16. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants.
    Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M.
    Am J Kidney Dis; 2012 May 06; 59(5):707-10. PubMed ID: 22196848
    [Abstract] [Full Text] [Related]

  • 17. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H.
    Clin Exp Nephrol; 2019 Jan 06; 23(1):65-75. PubMed ID: 29959568
    [Abstract] [Full Text] [Related]

  • 18. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
    Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P.
    Am J Kidney Dis; 2013 Feb 06; 61(2):289-99. PubMed ID: 23141475
    [Abstract] [Full Text] [Related]

  • 19. A case report of recurrent acute pancreatitis associated with life threatening atypical hemolytic uremic syndrome.
    Jean-Marie EM, Cho JJ, Trevino JG.
    Medicine (Baltimore); 2020 May 29; 99(22):e19731. PubMed ID: 32481360
    [Abstract] [Full Text] [Related]

  • 20. Nephromegaly in an infant with atypical hemolytic-uremic syndrome resolving successfully with eculizumab.
    Kumar G.
    Saudi J Kidney Dis Transpl; 2018 May 29; 29(4):967-970. PubMed ID: 30152436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.